Embecta Corp. (EMBC) faces a challenging fiscal 2026, with flat revenue and earnings growth expected - after a strong fiscal 2025. EMBC's weak outlook is driven by cannula costs, modest volume ...
Embecta Corp. (NASDAQ:EMBC) posted on Friday the second-quarter 2025 adjusted earnings of 70 cents per share, up from 67 cents a year ago, beating the consensus of 53 cents. The diabetes care company ...
Embecta faces accelerating revenue declines, with Q2 2026 sales down 14% and U.S. revenues plunging 29%. Click here to read ...
(1) Reflects the recognition of changes in estimates for the Italian payback measure relating to certain prior fiscal years between 2015 and 2023. (2) Represents stock-based compensation expense ...
Embecta Corp. recently reported second-quarter 2026 results showing sales of US$221.8 million and a net loss of US$4.1 million, and also approved a quarterly dividend of US$0.0100 per share payable on ...
PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results